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Abstract
Aims. The longitudinal relationship between depression and the risk of non-alcoholic fatty
liver disease is uncertain. We examined: (a) the association between depressive symptoms
and incident hepatic steatosis (HS), both with and without liver fibrosis; and (b) the influence
of obesity on this association.
Methods. A cohort of 142 005 Korean adults with neither HS nor excessive alcohol consump-
tion at baseline were followed for up to 8.9 years. The validated Center for Epidemiologic
Studies-Depression score (CES-D) was assessed at baseline, and subjects were categorised
as non-depressed (a CES-D < 8, reference) or depression (CES-D⩾ 16). HS was diagnosed
by ultrasonography. Liver fibrosis was assessed by the fibrosis-4 index (FIB-4). Parametric
proportional hazards models were used to estimate the adjusted hazard ratios (aHRs) and
95% confidence intervals (CIs).
Results. During a median follow-up of 4.0 years, 27 810 people with incident HS and 134 with
incident HS plus high FIB-4 were identified. Compared with the non-depressed category, the
aHR (95% CIs) for incident HS was 1.24 (1.15–1.34) for CES-D⩾ 16 among obese indivi-
duals, and 1.00 (0.95–1.05) for CES-D⩾ 16 among non-obese individuals ( p for interaction
with obesity <0.001). The aHR (95% CIs) for developing HS plus high FIB-4 was 3.41
(1.33–8.74) for CES-D⩾ 16 among obese individuals, and 1.22 (0.60–2.47) for CES-D⩾ 16
among non-obese individuals ( p for interaction = 0.201).
Conclusions. Depression was associated with an increased risk of incident HS and HS plus
high probability of advanced fibrosis, especially among obese individuals.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a global health problem with a prevalence of
approximately 25% worldwide (Maurice and Manousou, 2018). The prevalence of
NAFLD-related advanced hepatic fibrosis, which leads to increased mortality risk, is also
steadily increasing (Kim et al., 2019a). NAFLD is predicted to become the most common indi-
cation for liver transplantation in the following decade (Maurice and Manousou, 2018).
However, there is no licensed pharmacological treatment for NAFLD, and lifestyle modifica-
tion with weight loss continues to be the mainstay of NAFLD management, underscoring the
importance of identifying modifiable risk factors for NAFLD and its progression (Maurice and
Manousou, 2018).
Depression is a leading cause of disability worldwide (World Health Organization, 2017),
with a lifetime prevalence of 6.5–21.0%. Depression also imposes a great burden on public
health worldwide (Kessler and Bromet, 2013). A growing body of evidence suggests that
depression is associated with increased risk of mortality, as well as various chronic diseases
including obesity, hypertension, diabetes, coronary artery disease and stroke. All of these
comorbidities are also commonly accompanied by NAFLD (Luppino et al., 2010; Dong
et al., 2012; Cuijpers et al., 2014; Lichtman et al., 2014). However, the specific relationship
between depression and NAFLD remains uncertain. Previous studies addressing this subject
have reported inconsistent results, varying from a positive association (Jung et al., 2019;
Kim et al., 2019b) to no evidence of an association (Surdea-Blaga and Dumitrascu, 2011;
Lee et al., 2013). However, many of these prior studies were limited by small sample sizes,
ambiguous temporality due to cross-sectional designs and various definitions of NAFLD,
depression and control groups. Previous studies on NAFLD have also shown that depression
is associated with a higher steatosis grade and more severe histology (Youssef et al., 2013;
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Tomeno et al., 2015). In addition, obesity is closely associated
with both NAFLD and depression (Buzzetti et al., 2016;
Jantaratnotai et al., 2017), and may act as a mediator or effect
modifier in the relationship between depression and NAFLD.
Depression and obesity often co-exist (Jantaratnotai et al.,
2017), and previous studies have suggested a synergistic effect
of the co-existence of depression and obesity on adverse health
outcomes such as coronary heart disease risk (Ladwig et al.,
2006; Yakar and Ertekin, 2018).
Until now, no longitudinal cohort studies have investigated the
effect of depression on NAFLD development and tested effect
modification by obesity. Therefore, in obese and non-obese sub-
jects without hepatic steatosis (HS) who had a low probability
of liver fibrosis at baseline, we examined whether depression is
associated with: (a) an increased risk of incident HS and (b) HS
plus high probability of advanced fibrosis.
Methods
Study population
The Kangbuk Samsung Health Study is a cohort including Korean
men and women who received comprehensive annual or biennial
health examinations at the Seoul and Suwon Kangbuk Samsung
Hospital Total Healthcare Centers (Chang et al., 2016; 2019). In
South Korea, the Industrial Safety and Health Law mandates
annual or biennial health screening exams for employees. The
study population participated in health screening examinations
from March 2011 to December 2017, and had at least one
follow-up visit by 31 December 2019 (N = 286 969). More than
80% of participants were employees of companies or local govern-
mental organisations, or their spouses, while the remaining parti-
cipated voluntarily in the health check-up programmes.
A total of 144 964 subjects met one or more exclusion criteria
at baseline (Fig. 1), and men who consumed alcohol ⩾30 g/day
and women who consumed ⩾20 g/day were also excluded. The
final sample included 142 005 participants. This study was
approved by the Institutional Review Board of Kangbuk
Samsung Hospital (IRB 2020-04-007) and conformed to the
1964 Declaration of Helsinki and its later amendments. The
requirement for informed consent was waived due to the use of
a preexisting de-identified dataset that was routinely collected
during the health screening process.
Data collection
Data regarding demographic and behavioural factors, medical his-
tory and current medication were collected using standardised
self-administered questionnaires. Participants were categorised
as never, former or current smokers. Current alcohol consump-
tion was assessed by the frequency of alcohol consumption per
week and the amount of alcohol intake per drinking day. The fre-
quency and amount consumed per drinking day were then used
to calculate average alcohol consumption per day. The level of
physical activity was determined through the validated Korean
version of the International Physical Activity Questionnaire
(IPAQ) Short Form (Craig et al., 2003; Chun, 2012).
Health-enhancing physical activity (HEPA) was defined when
one of the two following criteria were met: (1) vigorous activity
on ⩾3 days/week with ⩾1500 of accumulated metabolic equiva-
lent (MET)-minutes/week (1 MET is equivalent to energy
expenditure at rest); or (2) 7 days of walking, moderate intensity
or vigorous intensity activities combined resulting in ⩾3000 MET
min/week (Craig et al., 2003). Usual dietary consumption during
the past year was assessed using a 106-item Korean version of self-
administered food frequency questionnaire (Ahn et al., 2007). The
20-item Korean version of the Center for Epidemiological
Studies-Depression (CES-D) was used to evaluate depressive
symptoms, for which the internal consistency has been reported
to range from 0.84 to 0.91 (Cho and Kim, 1998). The presence
of clinically significant depressive symptoms was defined at base-
line as a CES-D score ⩾16, which has been established and vali-
dated as identifying depression in previous studies (Beekman
et al., 1997; Cho et al., 1998). The non-depressed group (identi-
fied as CES-D < 8) was used as the reference because the negative
impact of less severe depressive symptoms (described as sub-
threshold depression) on various health outcomes has been
reported compared to a non-depressed group (Hybels et al.,
2001; Vahia et al., 2010; Cuijpers et al., 2013). Thus, for this
study, the CES-D scores were categorised as non-depressed
(CES-D < 8), sub-threshold depression (CES-D: 8–15) and
depression (CES-D ⩾ 16) (Hybels et al., 2001; Vahia et al., 2010;
Cuijpers et al., 2013).
Patient seated blood pressure (BP), height and weight mea-
surements were obtained by trained nurses. Obesity was defined
as body mass index (BMI)⩾ 25 kg/m2, the proposed cutoff for
obesity diagnosis in Asians (World Health Organization and
Regional Office for the Western Pacific, 2000). Hypertension
was identified through systolic BP ⩾140 mmHg, diastolic BP
⩾90 mmHg, or the use of any antihypertensive medications.
Laboratory analyses
Blood specimens were obtained after fasting for >10 h. The blood
measurements included the following: total cholesterol, low-
density lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), triglycerides, glucose, insulin, albumin,
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), gamma-glutamyltransferase and platelets (Chang et al.,
2016). Insulin resistance was evaluated using the homoeostatic
model assessment-insulin resistance (HOMA-IR) equation as fol-
lows: fasting blood insulin (μU/ml) × fasting blood glucose (FBG)
(mmol/l)/22.5. Diabetes mellitus was defined as FBG ⩾126 mg/dl,
haemoglobin A1c (HbA1c) ⩾6.5% or current use of anti-diabetic
medication.
The diagnosis of HS was based on abdominal ultrasounds per-
formed by experienced radiologists blinded to the aim of this
study. Diagnosis was based on standard criteria: diffuse increase
of fine echoes in the liver parenchyma compared with the kidney
or spleen parenchyma, deep beam attenuation and bright vessel
walls (Mathiesen et al., 2002). Inter- and intra-observer reliability
values for diagnoses of HS were substantial (kappa statistic of
0.74) and excellent (kappa statistic of 0.94), respectively (Kim
et al., 2013, 2019c; Chang et al., 2018).
To evaluate the risk of more severe HS, we used two non-
invasive indices of liver fibrosis: the fibrosis-4 (FIB-4) score,
and the NAFLD fibrosis score (NFS) (Angulo et al., 2007; Shah
et al., 2009). The FIB-4 index was calculated as FIB-4 = (age
(years) × AST (U/l))/(platelet count ( × 109/l) × ALT (U/l)1/2)
(Shah et al., 2009). The NFS was calculated as NFS =−1.675 +
0.037 × age (years) + 0.094 × BMI (kg/m2) + 1.13 × impaired fast-
ing glucose or diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio
− 0.013 × platelet ( × 109/l)− 0.66 × albumin (g/dl) (Angulo
et al., 2007). FIB-4 of ⩾2.67 or NFS of >0.676 cutoff values
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were used to identify high probability of advanced liver fibrosis,
and FIB-4 of 1.30 to 2.66 or NFS of 0.676 to −1.455 were used
to identify intermediate probability of advanced fibrosis
(Angulo et al., 2007; Shah et al., 2009).
Clinical and biochemical components of FIB-4, NFS and HS
based on abdominal ultrasound were collected as part of basic
health check-up programmes and thus FIB-4, NFS and HS
could be annually or biennially evaluated at each baseline and
follow-up visit for this study.
Statistical analysis
The baseline characteristics of the study participants were
described according to the CES-D category. Since there was a dif-
ference in age and sex between those with depression and those
without, the baseline characteristics were presented as age- and
sex-adjusted means or proportions and 95% confidence intervals
(CIs).
The primary endpoints were: (a) development of incident HS
and (b) development of incident HS plus high probability of
advanced fibrosis based on FIB-4 scores. Incident HS and inci-
dent HS plus high fibrosis score were treated as separate end-
points in each model. For analysis of the association between
depression and incident HS, if HS occurred during follow-up,
subsequent observations were not incorporated in further ana-
lysis. For analysis of the association between depression and inci-
dent HS plus high probability of advanced fibrosis, if an
individual’s ultrasonographic finding indicated HS and non-
invasive fibrosis markers showed high probability of advanced
fibrosis during follow-up, the case was assumed to have developed
HS plus high probability of advanced fibrosis. The event detection
date was defined as the earliest date of identification of HS or HS
plus high fibrosis score. The person-years were computed as the
sum of the follow-up duration from baseline to the event detec-
tion date (HS or HS plus high fibrosis score, separately) or until
the final examination (before 31 December 2019), whichever
occurred first. The incidence rates were computed as number of
incident cases divided by the person-years of follow-up. Either
primary endpoint would have occurred at an unknown time
point between the event detection date and the previous screening
visit. Therefore, we used a parametric proportional hazards model
for interval censoring, and the baseline hazard function was para-
meterised with restricted cubic splines in log time using four
degrees of freedom.
The risk of incident HS and HS plus high fibrosis score were
separately evaluated according to the CES-D category. The hazard
ratio (HR) and 95% CI were calculated using the parametric pro-
portional hazards model. The models were initially adjusted for
age and sex, and were then further adjusted for the following
potential confounders: study centre (Seoul, Suwon), year of
screening exam, smoking (never, past, current or unknown), alco-
hol intake (none, <10 g/day, ⩾10 g/day or unknown), physical
activity (inactive, minimally active, HEPA or unknown), BMI
(continuous), education level (<community college graduate,
⩾community college graduate or unknown), total energy intake,
diabetes, hypertension and history of cardiovascular disease
(CVD) (model 1). We next sought to examine whether the rela-
tionship between depression and development of the primary
endpoints was mediated by insulin resistance, inflammation and
metabolic abnormalities. Therefore, model 2 was further adjusted
for HOMA-IR, high-sensitivity C-reactive protein (hs-CRP) and
other metabolic factors including systolic BP, glucose, total chol-
esterol, HDL-C and triglycerides. We assessed the proportional
hazards assumption by examining graphs of estimated log(−log
(survival)) v. log of survival time graph: no violation of the
assumption was found.
We then evaluated whether or not the associations between
depressive symptoms and the risk of HS or HS plus high
fibrosis score differed by the presence of obesity (as defined by
BMI ⩾ 25 kg/m2) (World Health Organization and Regional
Office for the Western Pacific, 2000), because the effect of depres-
sion on various clinical outcomes appears to be increased by the
presence of obesity (Ladwig et al., 2006; Yakar and Ertekin, 2018).
The interactions between the CES-D categories and obesity on the
risk of HS, and the high probability of advanced liver fibrosis were
tested using likelihood ratio tests. These tests compare models
Fig. 1. Flowchart of study participants.
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with and without multiplicative interaction terms. Sensitivity ana-
lyses were performed using NFS as another validated non-invasive
liver fibrosis score. We also performed time-dependent analyses
with CES-D score category, BMI, smoking status, alcohol con-
sumption, physical activity, total energy intake, diabetes, hyper-
tension and history of CVD as time-varying covariates. ‘p for
linear trend’ was tested by including the CES-D categories as a
continuous variable on each model.
The statistical analyses were performed using STATA version
16.0 (StataCorp LP, College Station, TX, USA). All reported p
values were two-tailed. Differences with a p value <0.05 were con-
sidered statistically significant.
Results
Table 1 shows the baseline characteristics of 142 005 participants
by CES-D categories. The proportions of people with sub-
threshold depression (CES-D; 8–15) and depression (CES-D ⩾
16) were 25.6 and 11.9%, respectively (Table 1). Participants
with depression were more likely to be younger and female than
the non-depressed. After adjusting for age and sex, depression
was positively associated with current smoking, alcohol intake,
diabetes, hypertension, history of CVD, total calorie intake and
slightly elevated glucose and triglyceride levels. In contrast,
depression was inversely associated with the educational level.
During a median follow-up of 4.0 years (interquartile range, 2.2–
6.0 years; maximum, 8.9 years; a total of 606 576.2 person-years), 27
810 participants developed HS (incidence rate, 45.8 per 1000
person-years) and 134 participants developed HS plus high FIB-4
(incidence rate, 20.0 per 100 000 person-years). Depression was
weakly and positively associated with an increased risk of HS, but
this association was more evident in obese individuals than it was
in non-obese individuals (Table 2). After adjusting for age, sex, cen-
tre, year of screening exam, education level, BMI, smoking status,
physical activity, total energy intake, diabetes, hypertension and his-
tory of CVD, the adjusted HR (95% CI) for incident HS comparing
CES-D⩾ 16 to CES-D < 8 was 1.24 (1.15–1.34), among participants
with obesity, whereas the corresponding adjusted HR (95% CI) was
1.00 (0.95–1.05) among those without obesity ( p for interaction by
obesity < 0.001). After further adjustment for HOMA-IR, hs-CRP
and other metabolic factors (including systolic BP, glucose, total
cholesterol, HDL-cholesterol and triglycerides), these associations
were similarly observed.
Table 3 shows the risk of incident HS plus high FIB-4 accord-
ing to depression and obesity. The association between depression
and the risk of HS plus high FIB-4 tended to be stronger among
obese individuals than non-obese individuals, although the differ-
ence was not statistically significant ( p for interaction = 0.201).
The multivariable adjusted HR (95% CI) for the development
of HS plus high FIB-4 comparing CES-D⩾ 16 to CES-D of <8
were 3.41 (1.33–8.74), among participants with obesity, whereas
the corresponding HRs (95% CI) among non-obese individuals
were 1.22 (0.60–2.47). Further adjustment for HOMA-IR,
hs-CRP and other metabolic factors did not change qualitatively.
These patterns were similarly observed in the sensitivity analyses
using a high NFS of >0.676 instead of high FIB-4 (online
Supplementary Table 1). In a sensitivity analysis for HS plus
high FIB-4 by using FIB-4 cutoff score of 3.25, as recommended
by the American Association for the Study of Liver Diseases
guidelines (Chalasani et al., 2018), the associations between
depression and risk of HS plus high FIB-4 were consistently
observed in the obese group (online Supplementary Table 3). In
time-dependent analyses where CES-D scores and other confoun-
ders were updated as time-varying covariates, the risk for HS
remained highest in obese subjects with depressive symptoms
while the association between CES-D categories and risk of HS
plus high fibrosis score was no longer significant (online
Supplementary Table 2).
Although we excluded men and women who consumed alco-
hol ⩾30 and ⩾20 g/day, respectively at baseline, we also conducted
a sensitivity analysis for HS and HS plus high fibrosis score after
excluding subjects who reported binge drinking (⩾6 drinks per
occasion). We found that depression remained positively asso-
ciated with HS and HS plus high fibrosis score, especially
among obese subjects (online Supplementary Table 4).
Discussion
Our novel results in a cohort of 142 852 Korean young and
middle-aged individuals demonstrate a longitudinal relationship
between depression at baseline and the development of NAFLD,
including both HS (diagnosed by ultrasound) and HS plus high
probability of advanced fibrosis based on the use of two non-
invasive fibrosis indices (FIB-4 and NFS). Our results also dem-
onstrate that the associations appear to be more pronounced in
individuals with obesity than in those without obesity, which sug-
gests that obesity adversely affects the association between depres-
sion and NAFLD. Our findings suggest that depression may
contribute to the development of HS and fibrosis, with a poten-
tially synergistic effect of combined depression and obesity.
Previous studies have examined the association between
depression and NAFLD. Some studies found a positive association
between depression and NAFLD (Jung et al., 2019; Kim et al.,
2019b), while others showed no association (Surdea-Blaga and
Dumitrascu, 2011; Lee et al., 2013). However, the previous studies
that found no association between depression and NAFLD were
limited in the following ways: small sample size (Surdea-Blaga
and Dumitrascu, 2011); the use of a NAFLD definition that was
based on elevated ALT (Lee et al., 2013); the comparison of
NAFLD subjects with individuals affected by other chronic liver
diseases such as chronic hepatitis C or alcohol-related liver dis-
ease, rather than to those without liver disease (Surdea-Blaga
and Dumitrascu, 2011; Lee et al., 2013). In contrast, in a cross-
sectional study using a nationally representative sample of the
United States population, depression was associated with 1.6–
2.2-fold increased prevalence of NAFLD, but not with
NAFLD-related advanced fibrosis (Kim et al., 2019b). In that
study, after adjusting for diabetes, obesity and insulin resistance,
the association between depression and NAFLD was attenuated
but remained statistically significant, indicating that the associ-
ation between depression and NAFLD may be mediated, in
part, by metabolic factors including obesity (Kim et al., 2019b).
Our cohort study extends these findings by demonstrating a lon-
gitudinal relationship between depression and HS plus high prob-
ability of advanced fibrosis based on non-invasive fibrosis indices,
FIB-4 and NFS. Furthermore, our study also demonstrates that
the association with HS alone and HS plus high fibrosis score
were more pronounced in individuals with obesity than the non-
obese. These results suggest that depression may adversely affect
NAFLD, especially in the presence of obesity.
Our findings of the association between depression and HS
plus high fibrosis score are in line with previous findings. One
short-term follow-up study of 258 patients with biopsy-proven
NAFLD demonstrated an association between depression, severe
4 In Young Cho et al.
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histological steatosis and higher NAFLD activity scores at baseline
(Tomeno et al., 2015). Another cross-sectional study of 567
patients with biopsy-proven NAFLD showed that depression
was associated in a dose-dependent manner with more severe
hepatocyte ballooning (Youssef et al., 2013). However, the tem-
poral relationship between depression and NAFLD severity
remained unclear based on these prior studies. Findings from
patients that underwent liver biopsy at university hospitals
might not be generalisable to the low-risk or average-risk general
population. Our study reveals an association between depression
and the development of more severe HS plus high probability
of advanced fibrosis in a generally healthy population using non-
invasive biomarkers. This relationship was particularly true in the
presence of obesity. This finding supports the notion that
Table 1. Baseline characteristicsa stratified by CES-D score category (n = 142 005)
Characteristics
CES-D score category
p value for trend<8 8–15 ⩾16
Number 88 655 36 389 16 961
Age (years) 35.9 (35.9–35.9) 36.1 (36.0–36.1) 34.8 (34.7–34.9) <0.001
Male (%) 44.6 (44.3–44.9) 37.9 (37.4–38.4) 23.6 (22.9–24.2) <0.001
Current smoker (%) 12.6 (12.4–12.8) 15.2 (14.8–15.6) 17.9 (17.2–18.5) <0.001
Alcohol intake (%)b 24.6 (24.4–24.9) 26.4 (26.0–26.8) 28.4 (27.7–29.0) <0.001
HEPA (%) 14.6 (14.4–14.9) 14.2 (13.9–14.6) 14.3 (13.8–14.9) 0.100
High education level (%)c 88.9 (88.7–89.1) 82.4 (82.0–82.7) 81.2 (80.6–81.8) <0.001
Hypertension (%) 4.2 (4.0–4.3) 4.2 (4.0–4.4) 4.5 (4.2–4.9) 0.085
Diabetes (%) 0.6 (0.5–0.6) 0.6 (0.5–0.7) 0.8 (0.6–0.9) 0.026
History of CVD (%) 0.4 (0.4–0.5) 0.6 (0.5–0.6) 0.8 (0.6–0.9) <0.001
Medication for dyslipidaemia (%) 0.8 (0.7–0.8) 0.8 (0.7–0.8) 0.7 (0.6–0.8) 0.402
History of depression (%) 0.3 (0.3–0.4) 0.5 (0.4–0.5) 0.9 (0.8–1.1) <0.001
Obesity (%)d 12.1 (11.9–12.3) 12.1 (11.7–12.4) 12.7 (12.2–13.3) 0.087
Body mass index (kg/m2) 21.9 (21.9–21.9) 21.9 (21.8–21.9) 21.9 (21.8–21.9) 0.819
Systolic BP (mmHg) 105.0 (104.9–105.1) 104.9 (104.8–105.0) 104.6 (104.4–104.7) <0.001
Diastolic BP (mmHg) 66.9 (66.9–67.0) 67.0 (66.9–67.1) 66.9 (66.7–67.0) 0.979
Glucose (mg/dl) 91.2 (91.1–91.2) 91.3 (91.2–91.4) 91.3 (91.1–91.4) 0.026
Total cholesterol (mg/dl) 187.1 (186.8–187.3) 186.5 (186.2–186.8) 187.3 (186.9–187.8) 0.741
LDL-C (mg/dl) 113.4 (113.3–113.6) 112.8 (112.5–113.1) 113.3 (112.9–113.7) 0.031
HDL-C (mg/dl) 63.2 (63.1–63.3) 62.9 (62.7–63.0) 63.0 (62.8–63.2) 0.004
Triglycerides (mg/dl) 86.4 (86.1–86.7) 86.9 (86.5–87.4) 87.2 (86.5–87.9) 0.006
AST (U/l) 18.9 (18.9–18.9) 18.9 (18.8–18.9) 18.7 (18.6–18.8) <0.001
ALT (U/l) 17.2 (17.2–17.3) 17.2 (17.1–17.3) 17.0 (16.9–17.2) <0.001
GGT (U/l) 20.2 (20.1–20.4) 20.9 (20.7–21.1) 20.7 (20.4–21.0) <0.001
Albumin (g/dl) 4.6 (4.6–4.6) 4.6 (4.6–4.6) 4.6 (4.6–4.6) <0.001
Platelet (×109/l) 250.3 (250.0–250.6) 250.7 (250.2–251.2) 252.8 (252.0–253.6) <0.001
hs-CRP (mg/l) 0.8 (0.8–0.9) 0.9 (0.8–0.9) 0.9 (0.8–0.9) 0.914
HOMA-IR 1.18 (1.18–1.19) 1.19 (1.18–1.19) 1.20 (1.19–1.21) 0.853
Fib-4 0.70 (0.70–0.70) 0.70 (0.69–0.70) 0.69 (0.69–0.69) <0.001
NFS −3.24 (−3.25 to ∼−3.24) −3.23 (−3.24 to ∼−3.22) −3.25 (−3.27 to ∼−3.24) 0.598
Total calorie intake (kcal/day)e 1114.3 (1108.7–1119.8) 1064.6 (1055.9–1073.3) 1158.4 (1145.6–1171.3) <0.001
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; CES-D, Center for Epidemiologic Studies-Depression Score; FIB-4, fibrosis-4; GGT, gamma-glutamyl
transpeptidase; HDL-C, high-density lipoprotein-cholesterol; hs-CRP, high sensitivity C-reactive protein; HEPA, health enhancing physical activity; HOMA-IR, homoeostasis model assessment
of insulin resistance; LDL-C, low-density lipoprotein cholesterol; NFS, non-alcoholic fatty liver disease fibrosis score.
aAge- and sex-adjusted mean or proportion with 95% CIs.
b⩾10 g of ethanol per day.
c⩾College graduate.
dBMI⩾ 25 kg/m2.
eAmong 105 083 participants with a plausible estimated energy intake level (within three standard deviations of the log-transformed mean energy intake).
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individuals with depression, but without NAFLD at baseline, may
be at increased risk of developing different degrees of NAFLD
(including both new-onset HS and HS plus high probability of
advanced fibrosis). However, when changes in CES-D, obesity
and other confounders were updated as time-varying covariates,
the association between depression and risk of HS remained stat-
istically significant, while the association with HS plus high fibro-
sis score did not; possibly longer time is required for depression to
affect the progression to HS plus high probability of advanced
fibrosis.
Although the underlying mechanisms between depression,
NAFLD and obesity remain unknown, a physiological stress
response affecting stress hormones, chronic inflammation, oxida-
tive stress, and insulin resistance may be involved. The pathogen-
esis of NAFLD is not completely understood, but is thought to
involve multiple insults that act together (Buzzetti et al., 2016).
A body of evidence suggests that depression is associated with
chronic low-grade inflammation, and increased inflammatory
cytokine levels including tumour necrosis factor, interleukin-1β
and interleukin-6 (Moylan et al., 2013; Miller and Raison, 2016;
Kohler et al., 2017). Excessive activity of the hypothalamic–pitu-
itary–adrenal axis, including elevated cortisol and corticotrophin-
releasing hormone, is implicated in the pathogenesis of depres-
sion (Varghese and Brown, 2001; Keller et al., 2017). Insulin
resistance, a key pathogenic feature, and its phenotypes (including
type 2 diabetes and metabolic syndrome) have been reported to be
associated with depression (Kan et al., 2013; Moulton et al., 2015;
Chan et al., 2019). Another possible mechanism of the
relationship between depression and NAFLD involves increased
monoamine oxidase-A (MAO-A) activity, which has been identi-
fied in depressed patients. MAO-A is thought to augment cellular
oxidative stress (Youssef et al., 2013). All of these characteristics,
accompanied by depression, might contribute to the development
of NAFLD and its progression. The role of obesity in the relation-
ship between depression and NAFLD may also be explained by
previous studies. Alterations in glucocorticoids, adipokines, insu-
lin resistance and increased inflammatory mediators, including
interleukin-6 and tumour necrosis factor alpha, are involved in
obesity. Depression and obesity may interact to create a vicious
cycle that potentiates NAFLD development (Kahn and Flier,
2000; Miller et al., 2003; Luppino et al., 2010; Hryhorczuk
et al., 2013; Ellulu et al., 2017).
Depression may also increase the risk of HS, and HS plus high
probability of advanced fibrosis through inadequate physical
activity and consumption of an unhealthy diet. Currently, there
are no approved treatments for NAFLD. Instead, it is managed
through lifestyle modification (Maurice and Manousou, 2018).
However, patients with NAFLD and major depressive disorder
generally respond poorly to standard care (Tomeno et al.,
2015). Therefore, it may be reasonable to screen and provide treat-
ment for depression in patients at high risk for HS and advanced
fibrosis. In this study, we adjusted for a wide range of covariates,
including lifestyle behaviours (such as low level of alcohol intake,
physical activity, smoking and total energy intake). Even after
these adjustments, depression appeared to be independently asso-
ciated with HS and HS plus high probability of advanced fibrosis.













Multivariable aHRa (95% CI)
2-Years 5-Years Model 1 Model 2
Overall (n = 142 005)
<8 375 354.4 17 819 47.5 70.1 212.9 1.00 (reference) 1.00 (reference) 1.00 (reference)
8–15 158 046.5 7232 45.8 65.3 203.3 1.02 (1.00–1.05) 1.03 (1.00–1.06) 1.03 (1.00–1.06)
⩾16 73 175.3 2759 37.7 50.8 166.9 1.07 (1.03–1.12) 1.06 (1.01–1.10) 1.07 (1.03–1.11)
p for trend <0.001 0.002 <0.001
Non-obese (n = 124 794)
<8 335 387.9 12 728 38.0 52.8 171.6 1.00 (reference) 1.00 (reference) 1.00 (reference)
8–15 142 561.0 5243 36.8 49.3 162.9 1.02 (0.99–1.05) 1.02 (0.99–1.06) 1.04 (1.00–1.07)
⩾16 66 881.6 1985 29.7 39.1 129.7 1.01 (0.96–1.06) 1.00 (0.95–1.05) 1.02 (0.98–1.07)
p for trend 0.401 0.502 0.072
Obese (n = 17 211)
<8 39 966.4 5091 127.4 188.4 495.0 1.00 (reference) 1.00 (reference) 1.00 (reference)
8–15 15 485.6 1989 128.4 184.3 502.7 1.05 (0.99–1.10) 1.05 (1.00–1.11) 1.03 (0.98–1.09)
⩾16 6293.7 774 123.0 153.3 486.8 1.25 (1.16–1.35) 1.24 (1.15–1.34) 1.25 (1.16–1.35)
p for trend <0.001 <0.001 <0.001
BMI, body mass index; CES-D, Center for Epidemiologic Studies-Depression Score; CI, confidence interval; aHR, adjusted hazard ratio; HDL-C, high density lipoprotein cholesterol; HOMA-IR,
homoeostasis model assessment of insulin resistance; hs-CRP, high sensitivity C-reactive protein.
aEstimated from parametric proportional hazard models. Multivariable model 1 was adjusted for age, sex, centre, year of screening exam, education level, BMI, smoking status, physical
activity, total energy intake, diabetes, hypertension and CVD; model 2: model 1 plus adjustment for systolic blood pressure, glucose, total cholesterol, triglyceride, HDL-C, HOMA-IR and
hs-CRP.
Note: p < 0.001 for the overall interaction between obesity and CES-D score category for incident HS (model 1).
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Our study has several limitations. First, although histological
diagnosis is the gold standard for liver disease, HS and liver fibro-
sis were assessed through ultrasound and two validated non-
invasive markers of liver fibrosis in our study. Throughout the
long period of follow-up, intra- and inter-observer agreement
tests between the radiologists were not performed on a regular
basis in our study. Different radiologists were involved over
time; however, all of them were unaware of the study aims.
Thus, it is likely that any misclassification would be non-
differential and would bias associations towards the null. Liver
biopsy is invasive, expensive and unfeasible to perform in a
large, generally healthy population. Non-invasive fibrosis mar-
kers, such as FIB-4 and NFS, have been validated as acceptable
diagnostic tools to identify biopsy-proven advanced liver fibrosis
(Angulo et al., 2007; Shah et al., 2009). A second limitation of
this study is that the depressive symptoms were evaluated using
a self-administered questionnaire, instead of a physician-
determined diagnosis. However, these types of questionnaires
are useful in population-based research. In addition, the CES-D
is one of the most widely used instruments to measure depression
and has been shown to have good reliability and validity for
depression assessment in a wide range of populations (Luckett
et al., 2010). Third, information regarding past medical history
and lifestyle behaviours were also collected through self-
administered questionnaires, which may have allowed for meas-
urement error. Some degree of residual confounding pertaining
to measurement errors and other unmeasured factors cannot be
excluded in the associations observed between depressive
symptoms and HS. Finally, our study subjects mostly consisted
of young and middle-aged, relatively healthy Koreans (of a pre-
dominantly single ethnicity), with high accessibility to health
care who participated in regular health examinations. Therefore,
our findings may not be generalisable to populations of other eth-
nicities and different demographic features.
Conclusion
In this large cohort study, depression was positively and inde-
pendently associated with incident HS and HS plus high probabil-
ity of advanced fibrosis in individuals with obesity. Further
research is needed to determine whether the assessment and treat-
ment of depression helps to prevent HS and related fibrosis, and
ultimately helps improve NAFLD prognosis, especially among
individuals with obesity.
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Multivariable aHRa (95% CI)
2-Years 5-Years Model 1 Model 2
Overall (n = 142 005)
<8 415 497.9 77 0.2 0.1 0.5 1.00 (reference) 1.00 (reference) 1.00 (reference)
8–15 174 664.8 42 0.2 0.1 0.5 1.35 (0.93–1.97) 1.38 (0.94–2.02) 1.39 (0.95–2.03)
⩾16 78 787.3 15 0.2 0.1 0.3 1.72 (0.98–3.00) 1.70 (0.97–2.98) 1.68 (0.96–2.95)
p for trend 0.388 0.026 0.026
Non-obese (n = 124 794)
<8 363 621.6 61 0.2 0.1 0.4 1.00 (reference) 1.00 (reference) 1.00 (reference)
8–15 154 299.8 30 0.2 0.1 0.4 1.21 (0.78–1.87) 1.24 (0.80–1.93) 1.26 (0.81–1.95)
⩾16 70 856.4 9 0.1 0.1 0.2 1.26 (0.62–2.55) 1.22 (0.60–2.47) 1.22 (0.60–2.47)
p for trend 0.349 0.357 0.340
Obese (n = 17 211)
<8 51 876.3 16 0.3 0.1 0.7 1.00 (reference) 1.00 (reference) 1.00 (reference)
8–15 20 365.0 12 0.6 0.2 0.9 1.91 (0.90–4.03) 1.92 (0.91–4.08) 1.93 (0.91–4.10)
⩾16 7930.9 6 0.8 0.0 0.8 3.60 (1.41–9.20) 3.41 (1.33–8.74) 3.55 (1.38–9.13)
p for trend 0.005 0.007 0.005
BMI, body mass index; CES-D, Center for Epidemiologic Studies-Depression Score; CI, confidence interval; FIB-4, fibrosis 4 index; aHR, adjusted hazard ratio; HDL-C, high density lipoprotein
cholesterol; HOMA-IR, homoeostasis model assessment of insulin resistance; hs-CRP, high sensitivity C-reactive protein.
aEstimated from parametric proportional hazard models. Multivariable model 1 was adjusted for age, sex, centre, year of screening exam, education level, BMI, smoking status, physical
activity, total energy intake, diabetes, hypertension and CVD; model 2: model 1 plus adjustment for systolic blood pressure, glucose, total cholesterol, triglyceride, HDL-C, HOMA-IR and
hs-CRP.
Note: p = 0.201 for the overall interaction between obesity and CES-D score category for incident HS plus high FIB-4 (model 1).
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